ciprofloxacin has been researched along with Brucellosis in 42 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Brucellosis: Infection caused by bacteria of the genus BRUCELLA mainly involving the MONONUCLEAR PHAGOCYTE SYSTEM. This condition is characterized by fever, weakness, malaise, and weight loss.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was designed to compare the efficacy of ciprofloxacin plus rifampin (CR) and ciprofloxacin plus doxycycline (CD) versus doxycycline plus rifampin (DR) in the treatment of brucellosis." | 9.14 | A comparative trial of three therapeutic regimens: ciprofloxacin-rifampin, ciprofloxacin-doxycycline and doxycycline-rifampin in the treatment of brucellosis. ( Hashemi, SH; Keramat, F; Mamani, M; Ranjbar, M; Zeraati, F, 2009) |
| "The present study was undertaken to evaluate the efficacy, safety, and patient tolerability of two antibiotic regimens for the treatment of brucellosis: rifampicin 600 mg/day and doxycycline 200 mg/day for 45 days (group 1), versus rifampicin 600 mg/day and ciprofloxacin 1 g/day for 30 days (group 2)." | 9.09 | Ciprofloxacin and rifampicin versus doxycycline and rifampicin in the treatment of brucellosis. ( Agalar, C; Turkyilmaz, R; Usubutun, S, 1999) |
| " In this study, among the patients of brucellosis, whose diseases were recently diagnosed, 50 patients, receiving one of the two common authentic regimens of doxycycline plus rifampin for eight weeks or ciprofloxacin plus rifampin for six weeks, were selected." | 7.77 | A comparison between doxycycline-rifampin and ciprofloxacin-rifampin regimens in the treatment of acute Brucellosis. ( Hassani, M; Nozadi, MS; Taghvaee, MR, 2011) |
| "In a relapsed case of brucellosis after short-term antibiotic therapy using doxycycline and ciprofloxacin two Brucella strains were isolated, before and after treatment." | 7.73 | Failure of a short-term antibiotic therapy for human brucellosis using ciprofloxacin. A study on in vitro susceptibility of Brucella strains. ( Al Dahouk, S; Hagen, RM; Neubauer, H; Nockler, K; Scholz, HC; Tomaso, H; Vergnaud, G; Wittig, M, 2005) |
| "With the aim to estimate the clinical and immunological efficiency of the ciprofloxacin (cifloxinal) 105 patients with acute (51), subacute (19) and chronic (35) brucellosis were studied." | 7.71 | [Ciprofloxacin in the treatment of patients with brucellosis]. ( Duĭsenova, AK; Kurmanova, GM; Kurmanova, KB, 2002) |
| "Brucellosis is a disease of domestic and wild animals that is transmitted to humans and exists worldwide." | 5.32 | Susceptibility of Mexican brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. ( Cardeñosa, O; Contreras-Rodríguez, A; Gutiérrez-Rubio, AT; Hernández-Oliva, GM; López-Merino, A; Migranas-Ortiz, R; Orrantia-Gradín, R, 2004) |
| " melitensis intraperitoneally on day 0 and were randomized to receive, starting on day 7, STR alone at 75, 150, or 300 mg/kg of body weight per day intraperitoneally or DOX at 6 mg/kg/day orally, RIF at 3 mg/kg/day orally, or CIP at 200 mg/kg/day orally, each of the last three drugs alone or in combination with STR at 75, 150, or 300 mg/kg/day, for 14 days." | 5.29 | Therapy of experimental murine brucellosis with streptomycin alone and in combination with ciprofloxacin, doxycycline, and rifampin. ( Lang, R; Rubinstein, E; Shasha, B, 1993) |
| "Ciprofloxacin is a quinolone that penetrates well intracellularly." | 5.28 | Failure of ciprofloxacin to eradicate brucellosis in experimental animals. ( al-Orainey, IO; Bashandi, AM; Saeed, EN, 1990) |
| "This study was designed to compare the efficacy of ciprofloxacin plus rifampin (CR) and ciprofloxacin plus doxycycline (CD) versus doxycycline plus rifampin (DR) in the treatment of brucellosis." | 5.14 | A comparative trial of three therapeutic regimens: ciprofloxacin-rifampin, ciprofloxacin-doxycycline and doxycycline-rifampin in the treatment of brucellosis. ( Hashemi, SH; Keramat, F; Mamani, M; Ranjbar, M; Zeraati, F, 2009) |
| "The present study was undertaken to evaluate the efficacy, safety, and patient tolerability of two antibiotic regimens for the treatment of brucellosis: rifampicin 600 mg/day and doxycycline 200 mg/day for 45 days (group 1), versus rifampicin 600 mg/day and ciprofloxacin 1 g/day for 30 days (group 2)." | 5.09 | Ciprofloxacin and rifampicin versus doxycycline and rifampicin in the treatment of brucellosis. ( Agalar, C; Turkyilmaz, R; Usubutun, S, 1999) |
| "The aim of this study was to assess in vitro antimicrobial susceptibility of Brucella melitensis isolates isolated from naturally infected sheep cases in an area where human brucellosis is endemic, focusing on rifampin (RIF), streptomycin (SM), ciprofloxacin (CPFX), trimethoprim/sulfamethoxazole (TMP/SMZ), gentamicin (GM) and tetracycline (TC) and on 11 other antimicrobials." | 3.79 | In vitro antimicrobial susceptibility of Brucella melitensis isolates from sheep in an area endemic for human brucellosis in Turkey. ( Ekin, IH; Ilhan, Z; Solmaz, H, 2013) |
| " Standard therapy (rifampicin plus doxycycline) of brucellosis was started, but the clinical and laboratory signs subsided after the addition of ciprofloxacin." | 3.79 | Renal cyst infection caused by Brucella abortus. ( Çörekli, E; Eşiyok, A; Köseoğlu, K; Öncü, S; Öztürk, B; Sakarya, S; Saylak, Ö, 2013) |
| " In this study, among the patients of brucellosis, whose diseases were recently diagnosed, 50 patients, receiving one of the two common authentic regimens of doxycycline plus rifampin for eight weeks or ciprofloxacin plus rifampin for six weeks, were selected." | 3.77 | A comparison between doxycycline-rifampin and ciprofloxacin-rifampin regimens in the treatment of acute Brucellosis. ( Hassani, M; Nozadi, MS; Taghvaee, MR, 2011) |
| "In a relapsed case of brucellosis after short-term antibiotic therapy using doxycycline and ciprofloxacin two Brucella strains were isolated, before and after treatment." | 3.73 | Failure of a short-term antibiotic therapy for human brucellosis using ciprofloxacin. A study on in vitro susceptibility of Brucella strains. ( Al Dahouk, S; Hagen, RM; Neubauer, H; Nockler, K; Scholz, HC; Tomaso, H; Vergnaud, G; Wittig, M, 2005) |
| "With the aim to estimate the clinical and immunological efficiency of the ciprofloxacin (cifloxinal) 105 patients with acute (51), subacute (19) and chronic (35) brucellosis were studied." | 3.71 | [Ciprofloxacin in the treatment of patients with brucellosis]. ( Duĭsenova, AK; Kurmanova, GM; Kurmanova, KB, 2002) |
| "The effectiveness of treatment of human brucellosis caused by Brucella melitensis with ciprofloxacin alone was investigated in a prospective nonrandomized study." | 3.68 | Efficacy of ciprofloxacin for treatment of Brucella melitensis infections. ( al-Sibai, MB; el-Shaker, MM; Halim, MA; Khan, BA; Qadri, SM, 1992) |
| "Brucellosis is among the most prevalent zoonotic infections in Middle Eastern and North African (MENA) countries, critically impacting human and animal health." | 2.82 | The perspective of antibiotic therapeutic challenges of brucellosis in the Middle East and North African countries: Current situation and therapeutic management. ( Al-Talhy, AM; Ali, H; Dadar, M; Elkharsawi, AR; Hamdy, MER; Neubauer, H; Tawab, AAAE; Wareth, G, 2022) |
| "Brucellosis is the most common zoonotic infection in the world." | 2.48 | Antibiotics for treating human brucellosis. ( Mehrani, M; Mortaz-Hejri, S; Sadeghipour, P; Yousefi-Nooraie, R, 2012) |
| "Although rare, reports of Brucella infection of prosthetic implants and devices have increased in the past decade." | 2.44 | Implantable cardioverter-defibrillator infection due to Brucella melitensis: case report and review of brucellosis of cardiac devices. ( Dhand, A; Ross, JJ, 2007) |
| "Brucellosis is a chronic disease caused by Brucella species with a wide range of hosts, from marine mammals to terrestrial species, but with strict host preferences." | 1.91 | The canonical Brucella species-host dependency is changing, however, the antibiotic susceptibility profiles remain unchanged. ( Abay, S; Akar, M; Aydin, F; Balkan Bozlak, CE; Baykal, A; Buyuk, E; Buyuk, F; Celebi, O; Celik, E; Coskun, MR; Durhan, S; Ersoy, Y; Gulmez Saglam, A; Karakaya, E; Kayman, T; Otlu, S; Sahin, M; Saticioglu, IB, 2023) |
| "Thyroiditis was diagnosed with clinical inspection and confirmed by ultrasound investigation." | 1.51 | Acute Thyroiditis Associated with Brucellosis: A Case Report. ( Bitoska, I; Bosilkovski, M; Cvetkova, M; Jakimovski, D; Poposki, K, 2019) |
| "Brucellosis is an important public health problem in Peru." | 1.37 | Antimicrobial susceptibility of Brucella melitensis isolates in Peru. ( Castillo, R; Cepeda, D; Chacaltana, J; Espinosa, B; Espinoza, N; González, S; Guillen, A; Hall, ER; Maves, RC; Meza, R; Núñez, G; Sánchez, L, 2011) |
| "Ciprofloxacin treatment reduced bacterial loads in the spleens of challenged mice when administered prior to or at the same time as the bacterial challenge." | 1.35 | Efficacy of ciprofloxacin versus doxycycline as prophylaxis against experimental murine Brucella melitensis infection. ( Atkins, HS; Brew, SD; Eley, SM; Jenner, DC; MacMillan, AP; Russell, P; Simpson, AJ; Spencer, S, 2009) |
| "In the Netherlands, brucellosis is uncommon." | 1.34 | Brucellosis, an uncommon and frequently delayed diagnosis. ( Bax, HI; Gyssens, IC; Rietveld, AP; van Veelen, ML, 2007) |
| "Brucellosis is a multisystemic disease." | 1.32 | A case of mitral stenosis complicated with seronegative Brucella endocarditis. ( Ibrisim, E; Kutsal, A; Ocal, A; Ozaydin, M; Ulusan, V; Yavuz, T, 2004) |
| "Brucellosis is a disease of domestic and wild animals that is transmitted to humans and exists worldwide." | 1.32 | Susceptibility of Mexican brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. ( Cardeñosa, O; Contreras-Rodríguez, A; Gutiérrez-Rubio, AT; Hernández-Oliva, GM; López-Merino, A; Migranas-Ortiz, R; Orrantia-Gradín, R, 2004) |
| "Brucellosis is a rare cause of spinal infections in the United States, although there have been regional increases in its prevalence." | 1.31 | Spinal brucellosis: case report in the United States. ( Reitman, CA; Watters, WC, 2002) |
| " melitensis intraperitoneally on day 0 and were randomized to receive, starting on day 7, STR alone at 75, 150, or 300 mg/kg of body weight per day intraperitoneally or DOX at 6 mg/kg/day orally, RIF at 3 mg/kg/day orally, or CIP at 200 mg/kg/day orally, each of the last three drugs alone or in combination with STR at 75, 150, or 300 mg/kg/day, for 14 days." | 1.29 | Therapy of experimental murine brucellosis with streptomycin alone and in combination with ciprofloxacin, doxycycline, and rifampin. ( Lang, R; Rubinstein, E; Shasha, B, 1993) |
| "Ciprofloxacin is a quinolone that penetrates well intracellularly." | 1.28 | Failure of ciprofloxacin to eradicate brucellosis in experimental animals. ( al-Orainey, IO; Bashandi, AM; Saeed, EN, 1990) |
| "Ofloxacin was the most active of the test antimicrobial agents." | 1.28 | Comparative in vitro activities of ofloxacin, difloxacin, ciprofloxacin, and other selected antimicrobial agents against Brucella melitensis. ( Dizon, M; Khan, MY; Kiel, FW, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.76) | 18.7374 |
| 1990's | 10 (23.81) | 18.2507 |
| 2000's | 19 (45.24) | 29.6817 |
| 2010's | 8 (19.05) | 24.3611 |
| 2020's | 3 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Wareth, G | 1 |
| Dadar, M | 1 |
| Ali, H | 1 |
| Hamdy, MER | 1 |
| Al-Talhy, AM | 1 |
| Elkharsawi, AR | 1 |
| Tawab, AAAE | 1 |
| Neubauer, H | 2 |
| Al-Faifi, J | 1 |
| Ibrahim, ME | 1 |
| Celik, E | 1 |
| Kayman, T | 1 |
| Buyuk, F | 1 |
| Gulmez Saglam, A | 1 |
| Abay, S | 1 |
| Akar, M | 1 |
| Karakaya, E | 1 |
| Balkan Bozlak, CE | 1 |
| Coskun, MR | 1 |
| Buyuk, E | 1 |
| Celebi, O | 1 |
| Sahin, M | 1 |
| Saticioglu, IB | 1 |
| Durhan, S | 1 |
| Baykal, A | 1 |
| Ersoy, Y | 1 |
| Otlu, S | 1 |
| Aydin, F | 1 |
| Cvetkova, M | 1 |
| Bitoska, I | 1 |
| Poposki, K | 1 |
| Jakimovski, D | 1 |
| Bosilkovski, M | 1 |
| Inayat, F | 1 |
| Mahboob, M | 1 |
| Ali, NS | 1 |
| Bokhari, SRA | 1 |
| Ashraf, A | 1 |
| Taghvaee, MR | 1 |
| Nozadi, MS | 1 |
| Hassani, M | 1 |
| Ilhan, Z | 1 |
| Solmaz, H | 1 |
| Ekin, IH | 1 |
| Barbosa Pauletti, R | 1 |
| Reinato Stynen, AP | 1 |
| Pinto da Silva Mol, J | 1 |
| Seles Dorneles, EM | 1 |
| Alves, TM | 1 |
| de Sousa Moura Souto, M | 1 |
| Minharro, S | 1 |
| Heinemann, MB | 1 |
| Lage, AP | 1 |
| Gallego Vilar, D | 1 |
| Povo Martín, I | 1 |
| Gimeno Argente, V | 1 |
| Bosquet, M | 1 |
| Rivadulla Serrano, I | 1 |
| Martínez Ramos, D | 1 |
| Gallego Gómez, J | 1 |
| Oztürk, O | 1 |
| Akçam, Z | 1 |
| Sahin, U | 1 |
| Bircan, A | 1 |
| Akkaya, A | 1 |
| Yayli, G | 1 |
| Atkins, HS | 1 |
| Spencer, S | 1 |
| Brew, SD | 1 |
| Jenner, DC | 1 |
| Russell, P | 1 |
| MacMillan, AP | 1 |
| Eley, SM | 1 |
| Simpson, AJ | 1 |
| Keramat, F | 1 |
| Ranjbar, M | 1 |
| Mamani, M | 1 |
| Hashemi, SH | 1 |
| Zeraati, F | 1 |
| Maves, RC | 1 |
| Castillo, R | 1 |
| Guillen, A | 1 |
| Espinosa, B | 1 |
| Meza, R | 1 |
| Espinoza, N | 1 |
| Núñez, G | 1 |
| Sánchez, L | 1 |
| Chacaltana, J | 1 |
| Cepeda, D | 1 |
| González, S | 1 |
| Hall, ER | 1 |
| Yousefi-Nooraie, R | 1 |
| Mortaz-Hejri, S | 1 |
| Mehrani, M | 1 |
| Sadeghipour, P | 1 |
| Öncü, S | 1 |
| Saylak, Ö | 1 |
| Köseoğlu, K | 1 |
| Öztürk, B | 1 |
| Eşiyok, A | 1 |
| Çörekli, E | 1 |
| Sakarya, S | 1 |
| Duĭsenova, AK | 1 |
| Kurmanova, KB | 1 |
| Kurmanova, GM | 1 |
| Bodur, H | 1 |
| Balaban, N | 1 |
| Aksaray, S | 1 |
| Yetener, V | 1 |
| Akinci, E | 1 |
| Colpan, A | 1 |
| Erbay, A | 1 |
| Kayaçetin, E | 1 |
| Türegen, A | 1 |
| Saritaş, U | 1 |
| Yavuz, T | 1 |
| Ozaydin, M | 1 |
| Ulusan, V | 1 |
| Ocal, A | 1 |
| Ibrisim, E | 1 |
| Kutsal, A | 1 |
| López-Merino, A | 1 |
| Contreras-Rodríguez, A | 1 |
| Migranas-Ortiz, R | 1 |
| Orrantia-Gradín, R | 1 |
| Hernández-Oliva, GM | 1 |
| Gutiérrez-Rubio, AT | 1 |
| Cardeñosa, O | 1 |
| Al Dahouk, S | 1 |
| Hagen, RM | 1 |
| Nockler, K | 1 |
| Tomaso, H | 1 |
| Wittig, M | 1 |
| Scholz, HC | 1 |
| Vergnaud, G | 1 |
| Alp, E | 1 |
| Koc, RK | 1 |
| Durak, AC | 1 |
| Yildiz, O | 1 |
| Aygen, B | 2 |
| Sumerkan, B | 1 |
| Doganay, M | 2 |
| Pappas, G | 1 |
| Christou, L | 1 |
| Akritidis, N | 1 |
| Tsianos, EV | 1 |
| Uncu, H | 2 |
| Demiroğlu, YZ | 1 |
| Gül, U | 1 |
| Güvel, S | 1 |
| Turunç, T | 1 |
| Cokaloğlu, S | 1 |
| Arslan, H | 2 |
| Dhand, A | 1 |
| Ross, JJ | 1 |
| Turan, H | 1 |
| Azap, OK | 1 |
| Serefhanoğlu, K | 1 |
| Bax, HI | 1 |
| van Veelen, ML | 1 |
| Gyssens, IC | 1 |
| Rietveld, AP | 1 |
| Coban, AY | 1 |
| Tanyel, E | 1 |
| Tasdelen Fisgin, N | 1 |
| Darka, O | 1 |
| Tulek, N | 1 |
| Durupinar, B | 1 |
| Monastirli, A | 1 |
| Vamvakopoulou, S | 1 |
| Georgiou, S | 1 |
| Marangos, M | 1 |
| Pasmatzi, E | 1 |
| Dimitracopoulos, G | 1 |
| Bassaris, H | 1 |
| Tsambaos, D | 1 |
| Lang, R | 3 |
| Shasha, B | 2 |
| Rubinstein, E | 2 |
| Sturniolo, G | 1 |
| Ricciardi, F | 1 |
| Ruggeri, P | 1 |
| Costantino, G | 1 |
| Pellicanò, GF | 1 |
| Bertuccio, O | 1 |
| La Rosá, F | 1 |
| Agalar, C | 1 |
| Usubutun, S | 1 |
| Turkyilmaz, R | 1 |
| Reitman, CA | 1 |
| Watters, WC | 1 |
| al-Sibai, MB | 2 |
| Halim, MA | 1 |
| el-Shaker, MM | 1 |
| Khan, BA | 1 |
| Qadri, SM | 2 |
| Raz, R | 1 |
| Sacks, T | 1 |
| Shapiro, M | 1 |
| al-Orainey, IO | 1 |
| Bashandi, AM | 1 |
| Saeed, EN | 1 |
| el-Yazigi, A | 1 |
| al-Rawithy, S | 1 |
| Khan, MY | 1 |
| Dizon, M | 1 |
| Kiel, FW | 1 |
| Bosch, J | 1 |
| Liñares, J | 1 |
| López de Goicoechea, MJ | 1 |
| Ariza, J | 1 |
| Cisnal, MC | 1 |
| Martin, R | 1 |
4 reviews available for ciprofloxacin and Brucellosis
| Article | Year |
|---|---|
The perspective of antibiotic therapeutic challenges of brucellosis in the Middle East and North African countries: Current situation and therapeutic management.
Topics: Animals; Anti-Bacterial Agents; Brucella melitensis; Brucellosis; Chloramphenicol; Ciprofloxacin; Do | 2022 |
Brucellosis in renal transplant recipients: a comparative review of 5 cases.
Topics: Anti-Bacterial Agents; Brucella melitensis; Brucellosis; Ciprofloxacin; Doxycycline; Humans; Kidney; | 2018 |
Antibiotics for treating human brucellosis.
Topics: Anti-Bacterial Agents; Brucellosis; Ciprofloxacin; Doxycycline; Humans; Ofloxacin; Randomized Contro | 2012 |
Implantable cardioverter-defibrillator infection due to Brucella melitensis: case report and review of brucellosis of cardiac devices.
Topics: Aged; Brucella melitensis; Brucellosis; Ciprofloxacin; Defibrillators, Implantable; Device Removal; | 2007 |
4 trials available for ciprofloxacin and Brucellosis
| Article | Year |
|---|---|
A comparative trial of three therapeutic regimens: ciprofloxacin-rifampin, ciprofloxacin-doxycycline and doxycycline-rifampin in the treatment of brucellosis.
Topics: Adult; Anti-Infective Agents; Brucellosis; Ciprofloxacin; Doxycycline; Drug Therapy, Combination; Fe | 2009 |
Doxycycline plus streptomycin versus ciprofloxacin plus rifampicin in spinal brucellosis [ISRCTN31053647].
Topics: Anti-Bacterial Agents; Brucellosis; Ciprofloxacin; Doxycycline; Drug Therapy, Combination; Humans; R | 2006 |
Ciprofloxacin and rifampicin versus doxycycline and rifampicin in the treatment of brucellosis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; | 1999 |
Failure of prolonged treatment with ciprofloxacin in acute infections due to Brucella melitensis.
Topics: Acute Disease; Adolescent; Adult; Brucellosis; Ciprofloxacin; Doxycycline; Female; Humans; Male; Mid | 1990 |
34 other studies available for ciprofloxacin and Brucellosis
| Article | Year |
|---|---|
Congenital brucellosis associated with subsequent Klebsiella pneumoniae co-infection in a premature neonate: A rare case report.
Topics: Amikacin; Anti-Bacterial Agents; Brucellosis; Ciprofloxacin; Coinfection; Female; Gentamicins; Human | 2022 |
The canonical Brucella species-host dependency is changing, however, the antibiotic susceptibility profiles remain unchanged.
Topics: Animals; Anti-Bacterial Agents; Brucella melitensis; Brucellosis; Cattle; Cefoperazone; Ciprofloxaci | 2023 |
Acute Thyroiditis Associated with Brucellosis: A Case Report.
Topics: Acute Disease; Anti-Bacterial Agents; Arthritis; Brucellosis; Ciprofloxacin; Gentamicins; Humans; Ma | 2019 |
A comparison between doxycycline-rifampin and ciprofloxacin-rifampin regimens in the treatment of acute Brucellosis.
Topics: Acute Disease; Anti-Bacterial Agents; Brucellosis; Ciprofloxacin; Doxycycline; Drug Therapy, Combina | 2011 |
In vitro antimicrobial susceptibility of Brucella melitensis isolates from sheep in an area endemic for human brucellosis in Turkey.
Topics: Animals; Anti-Bacterial Agents; Brucella melitensis; Brucellosis; Ciprofloxacin; DNA Primers; Gentam | 2013 |
Reduced Susceptibility to Rifampicin and Resistance to Multiple Antimicrobial Agents among Brucella abortus Isolates from Cattle in Brazil.
Topics: Animals; Anti-Bacterial Agents; Bacterial Typing Techniques; Brazil; Brucella abortus; Brucellosis; | 2015 |
[Brucella spp orchiepididymitis].
Topics: Anti-Bacterial Agents; Brucellosis; Ciprofloxacin; Doxycycline; Epididymitis; Humans; Male; Middle A | 2008 |
[A rare agent of pneumonia: Brucella melitensis].
Topics: Anti-Infective Agents; Brucella melitensis; Brucellosis; Ciprofloxacin; Cough; Diagnosis, Differenti | 2008 |
Efficacy of ciprofloxacin versus doxycycline as prophylaxis against experimental murine Brucella melitensis infection.
Topics: Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Brucella melitensis; Brucellosis; Ciprofloxa | 2009 |
Antimicrobial susceptibility of Brucella melitensis isolates in Peru.
Topics: Anti-Infective Agents; Azithromycin; Brucella melitensis; Brucellosis; Ciprofloxacin; Doxycycline; G | 2011 |
Renal cyst infection caused by Brucella abortus.
Topics: Brucella abortus; Brucellosis; Ciprofloxacin; Doxycycline; Drug Therapy, Combination; Emergency Serv | 2013 |
[Ciprofloxacin in the treatment of patients with brucellosis].
Topics: Acute Disease; Adult; Antibody Formation; Brucella melitensis; Brucellosis; Chronic Disease; Ciprofl | 2002 |
Biotypes and antimicrobial susceptibilities of Brucella isolates.
Topics: Anti-Bacterial Agents; Bacterial Typing Techniques; Brucella melitensis; Brucellosis; Ceftriaxone; C | 2003 |
Hepatic abscess in brucellosis: a case report.
Topics: Brucellosis; Ciprofloxacin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow- | 2003 |
A case of mitral stenosis complicated with seronegative Brucella endocarditis.
Topics: Adult; Brucella melitensis; Brucellosis; Ciprofloxacin; Combined Modality Therapy; Doxycycline; Drug | 2004 |
Susceptibility of Mexican brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis.
Topics: Anti-Bacterial Agents; Aza Compounds; Brucella; Brucellosis; Ciprofloxacin; Drug Resistance, Multipl | 2004 |
Failure of a short-term antibiotic therapy for human brucellosis using ciprofloxacin. A study on in vitro susceptibility of Brucella strains.
Topics: Anti-Infective Agents; Brucellosis; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Male; Microbi | 2005 |
Quinolones for brucellosis: treating old diseases with new drugs.
Topics: Anti-Infective Agents; Brucella; Brucellosis; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Qui | 2006 |
[A case of brucellosis presenting with urinary tract infection].
Topics: Acute Disease; Adult; Anti-Infective Agents; Brucella melitensis; Brucellosis; Ciprofloxacin; Humans | 2006 |
In vitro antibacterial activity of tigecycline in comparison with doxycycline, ciprofloxacin and rifampicin against Brucella spp.
Topics: Adult; Anti-Bacterial Agents; Brucella; Brucellosis; Ciprofloxacin; Doxycycline; Humans; Microbial S | 2007 |
Brucellosis, an uncommon and frequently delayed diagnosis.
Topics: Adult; Aged; Arthralgia; Back Pain; Brucellosis; Ciprofloxacin; Diagnosis, Differential; Doxycycline | 2007 |
Mutant prevention concentrations of tetracycline, rifampicin and ciprofloxacin for Brucellae melitensis.
Topics: Anti-Bacterial Agents; Brucella melitensis; Brucellosis; Ciprofloxacin; Drug Therapy, Combination; H | 2007 |
Acute brucellosis presenting as cellulitis.
Topics: Adult; Anti-Infective Agents; Brucellosis; Cellulitis; Ciprofloxacin; Doxycycline; Drug Therapy, Com | 2008 |
Therapy of experimental murine brucellosis with streptomycin alone and in combination with ciprofloxacin, doxycycline, and rifampin.
Topics: Animals; Body Weight; Brucella; Brucellosis; Ciprofloxacin; Colony Count, Microbial; Doxycycline; Dr | 1993 |
[Treatment of chronic brucellosis with ciprofloxacin. Personal experience].
Topics: Adult; Brucellosis; Chronic Disease; Ciprofloxacin; Female; Humans; Male; Middle Aged | 1993 |
Spinal brucellosis: case report in the United States.
Topics: Anti-Infective Agents; Brucella melitensis; Brucellosis; Cheese; Ciprofloxacin; Diskectomy; Female; | 2002 |
Therapy of experimental murine brucellosis with streptomycin, co-trimoxazole, ciprofloxacin, ofloxacin, pefloxacin, doxycycline, and rifampin.
Topics: Administration, Oral; Animals; Brucellosis; Ciprofloxacin; Doxycycline; Injections, Intraperitoneal; | 1992 |
Use of ciprofloxacin in the treatment of brucellosis.
Topics: Adolescent; Adult; Aged; Brucella; Brucellosis; Ciprofloxacin; Female; Humans; Male; Microbial Sensi | 1992 |
Efficacy of ciprofloxacin for treatment of Brucella melitensis infections.
Topics: Administration, Oral; Adult; Aged; Brucellosis; Ciprofloxacin; Drug Evaluation; Female; Follow-Up St | 1992 |
Failure of ciprofloxacin to eradicate brucellosis in experimental animals.
Topics: Animals; Brucellosis; Ciprofloxacin; Drug Evaluation, Preclinical; Drug Therapy, Combination; Mice; | 1990 |
Development of ciprofloxacin resistance in Brucella melitensis.
Topics: Brucella; Brucellosis; Ciprofloxacin; Drug Resistance, Microbial; Humans; Male; Middle Aged | 1990 |
A direct liquid chromatographic quantitation of ciprofloxacin in microsamples of plasma with fluorometric detection.
Topics: Brucellosis; Chromatography, Liquid; Ciprofloxacin; Fluorometry; Humans; Microchemistry | 1990 |
Comparative in vitro activities of ofloxacin, difloxacin, ciprofloxacin, and other selected antimicrobial agents against Brucella melitensis.
Topics: Anti-Infective Agents; Brucella; Brucellosis; Ciprofloxacin; Fluoroquinolones; Humans; Microbial Sen | 1989 |
In-vitro activity of ciprofloxacin, ceftriaxone and five other antimicrobial agents against 95 strains of Brucella melitensis.
Topics: Anti-Bacterial Agents; Brucella; Brucellosis; Ceftriaxone; Ciprofloxacin; Drug Combinations; Humans; | 1986 |